(P126) Long-Term Volumetric Follow-Up of Juvenile Pilocytic Astrocytomas Treated With Proton Beam Radiotherapy

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Pediatric patients with PAs can have extended survival following proton beam radiotherapy. This volumetric study illustrates that responders are declared within 6 months, but vigilant surveillance is necessary due to the potential need for postradiotherapy interventions.

Edward M. Mannina, MD, MPH, MS, Greg Bartlett, CMD, Peter A. Johnstone, MD, Kevin P. Mcmullen, MD; Indiana University School of Medicine; University Of South Florida

INTRODUCTION: Juvenile pilocytic astrocytomas (JPAs) are World Health Organization (WHO) grade 1 glial neoplasms treated by resection with radiotherapy reserved for inoperable cases or following subtotal resection. Proton radiotherapy minimizes integral dose and is thus preferred in children. We analyzed the magnetic resonance imaging (MRI) follow-up of patients with JPA treated with proton radiotherapy to define the volume changes, response rate, need for postradiotherapy intervention, and survival.

METHODS: A total of 15 pediatric patients histologically diagnosed with JPA made up this retrospective report. From August 2005 through March 2012, patients were treated to a median dose of 5,400 cGy (relative biological effectiveness [RBE]) using proton radiotherapy and then followed with serial MRIs for 3 years. MRIs were imported into Eclipse 11 treatment planning software, where contours of the T1 contrast-enhancing volumes, including cystic components, were generated by one clinical radiation oncologist (EMM). Volume in cm3 was plotted against time since completion of therapy to track volumetric changes. Demographics, prior therapies, and postradiotherapy interventions were cataloged.

RESULTS: This is a retrospective review of 15 patients with a mean age of 10.9 years (range: 4–20 yr) and mean number of 8.9 MRIs (range: 4–12). A total of 10 of 15 (67%) patients had prior R2 resections, with 3 patients having two R2 resections. Further, 12 of 15 (80%) patients had cerebrospinal fluid (CSF) shunts prior to radiotherapy, and 9 of 15 (60%) patients received prior chemotherapy, all with at least a platinum agent and vincristine. With a median follow-up of 55.3 months, 14 of 15 (93%) patients were alive, for an estimated 5-year overall survival (OS) of 93.3%. Median event-free survival (EFS) was 86.6 months, with an estimated 5-year EFS of 72.2%. A total of 11 of 15 (73.3%) patients were declared to be responders by 6 months, with 3 of 11 (27%) demonstrating pseudoprogression (increase in volume followed by spontaneous regression), with a mean time to maximum volume of 177 days. Also, 4 of 15 (26.7%) patients were nonresponders, including one who died of progression 9 months after radiotherapy and another who restarted chemotherapy. Three patients underwent shunt revisions, while two received hyperbaric oxygen, one for presumed radionecrosis and another for biopsy-proven radionecrosis (the only patient with prior radiation). Stereotactic cyst aspiration was required in one case. One heavily pretreated patient developed a hematologic malignancy requiring further chemotherapy. A total of 8 of 15 (53.3%) patients required no further therapy or intervention after radiotherapy. Gross tumor volume changes ranged from a 91% reduction to a 207% increase during the evaluation period.

CONCLUSIONS: Pediatric patients with PAs can have extended survival following proton beam radiotherapy. This volumetric study illustrates that responders are declared within 6 months, but vigilant surveillance is necessary due to the potential need for postradiotherapy interventions.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content